Dr. Iskandar Azwa: Second and Third-Line Treatment Options for HIV/AIDS Patients

Dr. Iskandar Azwa: Second and Third-Line Treatment Options for HIV/AIDS Patients

2024.02.18
Chairman of the Malaysian AIDS Council, Head of Infectious Diseases Department at the University of Malaya Medical Center. His research interests include pre-exposure prophylaxis (PrEP) implementation in key populations, HIV drug resistance, and evaluating new HIV treatment strategies. He is the principal investigator for several international collaborative HIV clinical trials, including TAHOD, START, and D2EFT studies.
APASL 2023 | Professor Li Jun: Latest Developments in ACLF Early Warning Models, Pioneering with Large-Scale Data from China

APASL 2023 | Professor Li Jun: Latest Developments in ACLF Early Warning Models, Pioneering with Large-Scale Data from China

2024.02.15
Acute-on-Chronic Liver Failure (ACLF) is a complex syndrome characterized by acute deterioration of liver function on the background of chronic liver disease, accompanied by liver and/or extrahepatic organ failure. It poses a significant challenge in internal medicine due to its high short-term mortality rate of 50% to 90%. Early prediction of the risk of ACLF in patients and advancing the treatment window can effectively improve patient outcomes.
ILCA 2023 | Molecular typing based on fatty acid degradation metabolism helps in achieving precision treatment for liver cancer.

ILCA 2023 | Molecular typing based on fatty acid degradation metabolism helps in achieving precision treatment for liver cancer.

2024.02.14
Primary liver cancer is currently the 4th most common malignant tumor and the 2nd leading cause of tumor-related death in China. 75%~85% of these cases are Hepatocellular carcinoma (HCC), posing a serious threat to the health and lives of Chinese citizens. In recent years, with the progress in traditional therapies like surgery, intervention, radiation, targeted therapy, and immunotherapy, there are now more options available for liver cancer patients. Recent clinical studies have shown that the combined treatment plan of atezolizumab and bevacizumab (referred to as “T+A”) can reduce the mortality risk of advanced liver cancer patients by 42% compared to the traditional targeted drug sorafenib, setting a new standard for the first-line treatment of advanced liver cancer. However, the overall survival rate of liver cancer patients remains unsatisfactory, with a 5-year survival rate of about 20%. Due to the heterogeneity of liver cancer, there is still a significant variance in the treatment response and prognosis of patients with the same clinical stage. How to select the most suitable individualized treatment method for different liver cancer patients, to maximize therapeutic effects, is a pressing issue in the clinic.
ILCA Expert Interview | Moving Forward Together! The Development and Prospects of Multidisciplinary Comprehensive Treatment of Liver Cancer

ILCA Expert Interview | Moving Forward Together! The Development and Prospects of Multidisciplinary Comprehensive Treatment of Liver Cancer

2024.02.14
Primary liver cancer is one of the common malignant tumors worldwide. With the development of modern biomedical technology, clinical surgical techniques, and minimally invasive treatment techniques, the surgical treatment level of liver cancer has made significant progress. At the recently concluded global academic event in the field of liver cancer - the 17th Annual Meeting of the International Liver Cancer Association (ILCA), Professor Myron Schwartz of Mount Sinai Hospital in the U.S. delivered a keynote report on the progress made in liver cancer surgical treatment in recent years. Our journal specially invited Professor Myron Schwartz for an in-depth interview on the evolution of future liver cancer clinical treatment strategies and the opportunities and challenges that liver cancer surgery will face. Here is the organized content for our readers.